Antares Pharma, Inc. (ATRS)

[jab91252]

It means, if they (Medac) goes ahead and launches/markets their product, Rasuvo (which is the subject of the current and ongoing litigation with Antares) and they end up on the losing end, they risk significant financial damages that would be awarded to Antares. Currently, Antares is asking for 'triple' damages.

And to be clear, the denial of Antares Citizens Petition from the FDA along with Antares not getting a temporary injunction to stop Medac, the original patent infringement first filed by Antares against Medac continues to work its way through the Court system. Those two things, the CP and TI, are procedural components that plaintiffs have available to them to use. To not explore those avenues and use them, would mean you have attorneys who are falling asleep at the switch. Any roadblock(s) should be explored and are by patent attorneys worth their salt.

In the end, Medac may very well launch their product before the litigation is settled - and to do so, assuming that some sort of settlement will be agreed upon by the parties, post launch.